MarketFriction

Alpa Laboratories Ltd

NSE ALPA · BSE 532878 · Pharmaceuticals
₹59.26 -0.42%
NSE close2026-10-01
52 week range46.10 - 93.85
Market cap₹126 Cr.
P/E31.2
Price band 20% Delivery 77.1%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Consolidated, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales32.3927.3123.6121.4424.9426.1539.9219.1126.2629.0531.4023.93
Expenses29.0424.8820.1020.9121.6225.4139.7218.6828.5127.5427.8027.89
Operating Profit3.352.433.510.533.320.740.200.43-2.251.513.60-3.96
OPM %10.34%8.90%14.87%2.47%13.31%2.83%0.50%2.25%-8.57%5.20%11.46%-16.55%
Other Income2.953.553.985.166.918.802.4811.943.060.91-0.165.77
Interest0.020.020.290.050.050.090.020.050.030.030.150.11
Depreciation0.490.660.520.540.530.550.580.550.670.650.220.72
Profit before tax5.795.306.685.109.658.902.0811.770.111.743.070.98
Tax %0.00%14.91%46.71%0.00%20.31%0.00%201.92%0.00%0.00%9.20%55.05%0.00%
Net Profit5.794.513.555.107.698.90-2.1211.770.111.591.380.98
EPS in Rs2.752.141.692.423.654.23-1.015.590.050.760.660.47
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales53636277859711293109110106111
Expenses47565876809010185100105103112
Operating Profit774168118953-1
OPM %13%11%7%1.5%7%8%10%9%8%4.4%3.1%-1.0%
Other Income53550411914231610
Interest121100000000
Depreciation133331212222
Profit before tax1065331120162126176
Tax %30%55%39%63%36%33%28%21%19%24%10%
Net Profit73312714131720154
EPS in Rs3.261.201.340.480.883.456.705.987.989.277.131.94
Dividend Payout %0%0%0%0%0%0%0%0%0%0%0%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth7%2%4%0%
Compounded Profit Growth8%24%6%-85%
Stock Price CAGR6%3%-7%-34%
Return on Equity7%10%11%8%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital212121212121212121212121
Reserves66727477777987101114131151165
Borrowings292411620062503
Other Liabilities132720182121332830255153
Total Liabilities128144126122121121140155167182223242
Fixed Assets515151086797112120
CWIP000001200000
Investments10121331495751757898118142
Other Assets11311897816558817182738480
Total Assets128144126122121121140155167182223242
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity-2-2217-13-118-21094189
Cash from Investing Activity37-8-2-11-15-116-162-13-12-11
Cash from Financing Activity7-6-159-5-105-43-52
Net Cash Flow42-360-15-2054-07-711
Free Cash Flow-3-3216-15-215-588-376
CFO/OP-92%-277%283%-263%102%324%15%123%155%85%466%369%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days156234168153142105133124184138155141
Inventory Days76196131138105901028184739273
Days Payable91244140134999815278100639798
Cash Conversion Cycle1411871591571499783127168149150116
Working Capital Days-520417420819412514011815213511071
ROCE %0%10%8%6%3%5%7%9%12%15%16%9%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters57.29%57.29%57.29%57.29%57.29%57.29%57.29%57.29%57.29%57.29%57.19%57.19%
FIIs0.11%0.95%0.50%0.36%0.74%0.35%0.40%0.36%0.35%0.36%0.38%0.35%
DIIs0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.07%
Public42.59%41.74%42.21%42.35%41.97%42.34%42.30%42.34%42.36%42.35%42.43%42.38%
No. of Shareholders18,56518,68218,69018,11618,88519,20618,87218,85118,54218,23617,90017,643

Fundamentals

Market Cap₹ 126 Cr.
Current Price₹ 60.4
Stock P/E31.2
Book Value₹ 88.5
ROCE9.40 %
ROE8.38 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)0%
Compounded Profit Growth (TTM)-85%
Consolidated figures.
Valuation
Market capRs 125 Cr
Enterprise valueRs 124 Cr
P/E (TTM)30.71x
Price to book0.67x
Price to sales1.13x
EV / EBITDA14.66x
EV / EBIT19.99x
EV / sales1.12x
Price to cash flow13.42x
Earnings yield3.26%
P/E, 3-year average9.38x
P/B, 3-year average0.98x
P/E, 5-year average9.51x
P/B, 5-year average1.00x
Profitability
Operating margin (excl. other income)3.11%
Operating margin (incl. other income)18.00%
EBITDA margin7.66%
Pre-tax margin5.33%
Net profit margin3.67%
Net margin, latest quarter4.10%
ROE8.38%
ROCE9.40%
ROA6.45%
ROE, 3-year average10.71%
ROCE, 3-year average13.15%
ROA, 3-year average8.55%
ROE, 5-year average10.85%
ROCE, 5-year average13.69%
ROA, 5-year average8.60%
ROIC (approx.)3.01%
Tax rate10.06%
Other income / net worth8.46%
Growth
Sales growth (latest year)-3.98%
Profit growth (latest year)-23.03%
Sales CAGR, 3 years4.46%
Sales CAGR, 5 years1.69%
Profit CAGR, 3 years6.06%
Profit CAGR, 5 years15.67%
Sales growth QoQ-23.79%
Profit growth QoQ-28.99%
Sales growth YoY (latest quarter)25.22%
Profit growth YoY (latest quarter)-91.67%
Per share
EPS (TTM)Rs 1.93
EPS (latest year)Rs 7.13
EPS (latest quarter)Rs 0.47
EPS, 3-year averageRs 8.13
EPS, 5-year averageRs 7.41
Book value per shareRs 88.53
Sales per shareRs 52.58
Cash flow per shareRs 4.42
Free cash flow per shareRs 2.85
Efficiency
Asset turnover0.44x
Fixed asset turnover5.25x
Inventory turnover5.57x
Inventory days65 days
Debtor days141 days
Debtors turnover2.59x
Creditor days98 days
Cash conversion cycle116 days
Working capital days71 days
Leverage
Total debtRs 3 Cr
Cash and bankRs 3 Cr
Net debtRs -0 Cr
Debt to equity0.01x
Net debt / EBITDA-0.04x
Interest coverage19.44x
Owners' fund to total sources76.93%
Debt to assets1.04%
Cash flow
Cash from Operating Activity (latest year)Rs 9 Cr
Cash from Investing Activity (latest year)Rs -11 Cr
Cash from Financing Activity (latest year)Rs 2 Cr
Net Cash Flow (latest year)Rs 1 Cr
Free cash flow (latest year)Rs 6 Cr
FCFE (approx.: FCF + change in debt)Rs 8 Cr
Cash from ops / profit, 5 years0.63x
Sales to cash flow11.39x
Statement figures
Net sales (TTM)Rs 111 Cr
Net sales (latest year)Rs 106 Cr
Sales (latest quarter)Rs 24 Cr
Operating profit excl. other income (latest year)Rs 3 Cr
Operating profit (latest quarter)Rs -4 Cr
Other income (TTM)Rs 10 Cr
EBITDA (TTM)Rs 8 Cr
PBDT (TTM)Rs 8 Cr
Profit before tax (TTM)Rs 6 Cr
Tax (latest year)Rs 2 Cr
Net profit (TTM)Rs 4 Cr
Net profit (latest year)Rs 15 Cr
Net profit (latest quarter)Rs 1 Cr
Depreciation (TTM)Rs 2 Cr
Depreciation (latest quarter)Rs 1 Cr
Interest (TTM)Rs 0 Cr
Cost of goods sold (latest year)Rs 74 Cr
Total expenditure (latest year)Rs 103 Cr
Total income (latest year)Rs 122 Cr
Share capitalRs 21 Cr
ReservesRs 165 Cr
Shareholders' fundsRs 186 Cr
Total assetsRs 242 Cr
Net blockRs 20 Cr
InvestmentsRs 142 Cr
ReceivablesRs 41 Cr
InventoryRs 13 Cr
Other liabilitiesRs 53 Cr
Shares outstanding (crore)2.10
Ownership
Promoter holding57.19% (-0.10 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/E 30.7 is at the 76th percentile of its own 9.4-year range (median 17.4, low 7.1, high 65.2).
P/B 0.67 is at the 28th percentile (median 0.95).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodALPANifty 50Difference
1 week+0.3%-2.8% +3.1 pts
1 month-4.0%-6.8% +2.8 pts
3 months-13.8%-7.6% -6.1 pts
6 months+27.6%+0.4% +27.1 pts
1 year-36.2%-9.9% -26.3 pts
2 years-49.4%-13.6% -35.8 pts
3 years-19.1%+14.2% -33.3 pts
5 years+11.7%+27.9% -16.2 pts

Red flags

F-score 3 of 8
explainDebt up, profit down Borrowings up 8267% while net profit fell in 2026
lookProfit leans on other income Other income was 94% of pre-tax profit in 2026
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Jun 2026
Sales ₹24 Cr +25.2% vs Jun 2025. Net profit ₹1 Cr -91.7%.
Against our estimate for Jun 2026: sales +32.0%, profit +9.5% in line. Our estimate for Sep 2026: sales Rs 27 Cr, profit Rs 1 Cr (how).

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
No bulk or block deals on record.
Ex-dateActionFactor
2024-09-20Annual General Meeting
2023-09-21Annual General Meeting
2022-09-20Annual General Meeting
2021-09-20 Annual General Meeting
2020-09-18 Annual General Meeting
2019-09-19 Annual General Meeting
2018-09-19 Annual General Meeting
2017-09-20 Annual General Meeting
2016-09-21 Annual General Meeting
2015-09-16 Annual General Meeting
2014-09-24Annual General Meeting
2013-07-31Annual General Meeting
2012-09-21Annual General Meeting
2011-09-22Annual General Meeting
2010-09-02Annual General Meeting
2009-07-23Annual General Meeting
2008-09-18Annual General Meeting
DateTypeWhat it says
2026-09-30Shareholder meetingProceedings of Annual General Meeting held on September 30, 2026
2026-09-17AppointmentAppointment of Ms Ms. Diksha Jaswani as Company Secretary of the company w.e.f. September 17, 2026.
2026-09-07Record DateRecord date for the purpose of Meeting is 22-Sep-2026.
2026-09-07AppointmentAppointment of Mrs RADHIKA as Non- Execut of the company w.e.f. September 05, 2026.
2026-08-13Board meeting outcomeAlpa Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-08-11UpdatesClarification board meeting date.
2026-07-29General UpdatesGeneral Updates
2026-07-27Reply to Clarification- FinaThe Exchange had sought clarification from Alpa Laboratories Limited for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (List...
2026-07-22CessationCessation of Ms.Jyoti Jain as Non- Executive Independent Director of the company w.e.f. July 21, 2026.
2026-07-08CessationCessation of Ms Yashoda Patidar as Company Secretary & Compliance Officer of the company w.e.f. July 26, 2026.
2026-06-25Clarification - Financial ReThe Exchange has sought clarification from Alpa Laboratories Limited for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (List...
2026-06-19Disclosure under SEBI TakeovAlpa Laboratories Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Sub...
2026-05-29Board meeting outcomeAlpa Laboratories Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
2026-04-11AppointmentAppointment of Ms.Yashoda Patidar as Company Secretary & Compliance Officer of the company w.e.f. April 11, 2026.
2026-04-09Price movementSignificant movement in price has been observed in Alpa Laboratories Limited. The Exchange, in order to ensure that investors have latest relevant inf...
2026-04-08Price movementSignificant movement in price has been observed in Alpa Laboratories Limited. The Exchange, in order to ensure that investors have latest relevant inf...
2026-03-09Disclosure under SEBI TakeovAlpa Laboratories Limited has submitted to the Exchange a copy of Disclosures under Regulation 10(6)-Report to stock Exchange in respect of any acquis...
2026-02-25ResignationResignation of Srashti Chopra as Company Secretary & Compliance Officer of the company w.e.f. March 25, 2026.
2026-02-11Board meeting outcomeBoard meeting held on February 11, 2026.
2026-02-11Board meeting outcomeAlpa Laboratories Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
2025-11-15Board meeting outcomeAlpa Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Order dateForumCase
2018-06-15CESTATALPA LABORATORIES LIMITED ---VS.--- INDORE
2018-05-30CESTATALPA LABORATORIES LIMITED ---VS.--- INDORE
Orders from NCLT, NCLAT and CESTAT naming the company. Click a row for the order.
Less than 100 unique PAN traded in previous 30 days

Quick answers

What is the market cap of Alpa Laboratories Ltd?

Alpa Laboratories Ltd (ALPA) has a market capitalisation of Rs 126 Cr. at the 2026-10-01 close.

What is the P/E ratio of Alpa Laboratories Ltd?

Alpa Laboratories Ltd trades at a P/E of 31.2 on trailing twelve-month profit, at the 2026-10-01 close.

What were Alpa Laboratories Ltd's latest quarterly results?

In the Jun 2026 quarter, Alpa Laboratories Ltd sales was Rs 24 Cr (+25.2% vs Jun 2025) and net profit was Rs 1 Cr.

What is the 52-week high and low of Alpa Laboratories Ltd?

The 52-week high is Rs 93.85 and the 52-week low is Rs 46.10.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03